Cyclophosphamide, bortezomib,anddexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

Blood

Volumn 119, Issue 19, 2012, Pages 4387-4390

  Venner, Christopher P ^a   Lane, Thirusha ^a   Foard, Darren ^a   Rannigan, Lisa ^a   Gibbs, Simon D J ^a   Pinney, Jennifer H ^a   Whelan, Carol J ^a   Lachmann, Helen J ^a   Gillmore, Julian D ^a   Hawkins, Philip N ^a   Wechalekar, Ashutosh D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; THALIDOMIDE; AMYLOID; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; HEART DISEASE; HEART FAILURE; HUMAN; LIGHT CHAIN DEPOSITION DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; TOXICITY; CLONAL EVOLUTION; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFECT; EVALUATION; FEMALE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AMYLOID; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLONAL EVOLUTION; COHORT STUDIES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860897399     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-388462     Document Type: Article

References (24)

1. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
2. Landau H, Hassoun H, Bello C, et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid. 2011;18(suppl 1):130-131.
3. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. The combination of cyclophosphamide-bortezomib-dexamethasone (CYBOR-D) Is a highly effective and well tolerated regimen that produces rapid and complete hematological response in patients with AL amyloidosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):3063.
4. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
5. Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489-1497.
6. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 2011;96(12):1890-1892.
7. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298. (Pubitemid 351397721)
8. Zonder J, Sanchorawala V, Snyder R, et al. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexamethasone. Amyloid. 2012;17(suppl):86-87.
9. Gidalevitz T, Kikis EA, Morimoto RI. A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr Opin Struct Biol. 2010;20(1):23-32.
10. Oliva L, Palladini G, Cerruti F, et al. Assessing proteostasis and proteasome stress in light chain amyloidosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):3992.
11. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90(2):201-206.
12. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-2266.
13. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341.
14. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328. (Pubitemid 41098849)
15. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. (Pubitemid 41095215)
16. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol. 2011;29(6):674-681.
17. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777-4782.
18. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-464. (Pubitemid 46105938)
19. Dubrey SW, Reece DE, Sanchorawala V, et al. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM. 2011;104(11):957-970.
20. Schonland SO, Dreger P, de Witte T, Hegenbart U. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis [published online ahead of print July 25, 2011]. Bone Marrow Transplant. doi: 10.1038/bmt.2011.152.
21. Gibbs SD, Gillmore JD, Sattianayagam PT, et al. In AL Amyloidosis, both oral melphalan and dexamethasone (Mel-Dex) and risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) have similar efficacy as upfront treatment [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):745.
22. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426-3430.
23. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51(12):2181-2187.
24. Wechalekar AD, Kastritis E, Merlini G, et al. European collaborative study of 153 patients with systemic AL amyloidosis with Mayo stage III disease. Haematologica. 2011;96(suppl 1):S158.